SynthesisWorld journal of gastroenterology2016
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.
Synthesis in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04186260 (A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men
Who cites it
51 citing papers in PubMed, 106 citations in OpenAlex.
- PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.Pharmacogenomics · 2024Trial
- Trial
- Evaluation of a new TyG indicator, TyHGB, in predicting non-alcoholic fatty liver disease: evidence from two independent populations.Lipids in health and disease · 2025Article
- Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2024Article
- A regulatory element associated to NAFLD in the promoter of DIO1 controls LDL-C, HDL-C and triglycerides in hepatic cells.Lipids in health and disease · 2024Article
- MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression.International journal of molecular sciences · 2023Article
- Transcriptomic analysis in zebrafish larvae identifies iron-dependent mitochondrial dysfunction as a possible key event of NAFLD progression induced by benzo[a]pyrene/ethanol co-exposure.Cell biology and toxicology · 2023Article
- Different Dietary Approaches, Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A Literature Review.Nutrients · 2023Review
- NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials.Frontiers in medicine · 2023Review
- TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.Hepatology forum · 2023Article
- MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population.Frontiers in endocrinology · 2023Article
- Genome Editing and Fatty Liver.Advances in experimental medicine and biology · 2023Review
- Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Development of a prediction protocol for the screening of metabolic associated fatty liver disease in children with overweight or obesity.Pediatric obesity · 2022Article
- Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative ReviewIranian biomedical journal · 2022Review
- Influence of Type 2 Diabetes in the Association ofBiomedicines · 2022Article
- GR-mediated transcriptional regulation of mJournal of animal science and biotechnology · 2021Article
- Liver disease in obesity and underweight: the two sides of the coin. A narrative review.Eating and weight disorders : EWD · 2021Review
- The effect of endurance training on non-alcoholic fatty liver disease in mice.Physiological reports · 2021Article
- Vitamins and non-alcoholic fatty liver disease: A Molecular InsightLiver research (Beijing, China) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate roles of genetic polymorphisms in non-alcoholic fatty liver disease (NAFLD) onset, severity, and outcome through systematic literature review.
methodsThe authors conducted both systematic and specific searches of PubMed through December 2015 with special emphasis on more recent data (from 2012 onward) while still drawing from more historical data for background. We identified several specific genetic polymorphisms that have been most researched and, at this time, appear to have the greatest clinical significance on NAFLD and similar hepatic diseases. These were further investigated to assess their specific effects on disease onset and progression and the mechanisms by which these effects occur.
resultsWe focus particularly on genetic polymorphisms of the following genes: PNPLA3, particularly the p. I148M variant, TM6SF2, particularly the p. E167K variant, and on variants in FTO, LIPA, IFNλ4, and iron metabolism, specifically focusing on HFE, and HMOX-1. We discuss the effect of these genetic variations and their resultant protein variants on the onset of fatty liver disease and its severity, including the effect on likelihood of progression to cirrhosis and hepatocellular carcinoma. While our principal focus is on NAFLD, we also discuss briefly effects of some of the variants on development and severity of other hepatic diseases, including hepatitis C and alcoholic liver disease. These results are briefly discussed in terms of clinical application and future potential for personalized medicine.
conclusionPolymorphisms and genetic factors of several genes contribute to NAFLD and its end results. These genes hold keys to future improvements in diagnosis and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.